Jim Meador Email and Phone Number
Jim Meador work email
- Valid
- Valid
- Valid
- Valid
Jim Meador personal email
Jim Meador phone numbers
An innovative and hands-on Group Leader for Protein Production that has created valuable assets and technology for all past companies. Most recently, created and optimized a novel, highly robust HTP cloning, expression, and purification process to reformat VHH and antibodies for mammalian expression, achieving throughputs of 1,000 to 2,000 per week. The cloning process is so efficient that minipreps give perfect DNA sequence data without picking colonies. Created a python script to codon optimize input sequences that helped achieve >95% successful expression and expression levels of VHH-Fc proteins average >400 µg/ml, and IgG >250 µg/ml.Extensive experience in the structural biology and glycobiology approach to drug discovery. Therapeutic areas include Oncology, Ophthalmology, Antivirals, Inflammation, and Autoimmunity. Proven expertise in project management, coaching and mentoring, inventive problem solving, and managing two teams to produce protein from CHO, HEK293, and E. coli. Particularly adept at streamlining complex biological processes including vector design, bispecific antibody expression and protein purification techniques. Extensive collaboration with many CRO partners to express mg to multi-gram quantities of glycan-modifying enzymes and antibodies, as well as to do antibody discovery and vector creation. Created HEK cell lines that express B4GalT1 or ST6Gal at 400 mg/liter, which helped the pursuit of M254, hyper-sialylated IVIg, for clinical trials. Led a team in cloning, expressing and purifying mg to gram quantities of low endotoxin antibodies from HEK293 and CHO-S cells for drug discovery. In less than 3 months, we expressed and purified >30 antibody candidates at >100 mg scale for animal model screening, engineering several framework modifications along the way, and ultimately came came up with M281, aka Nipocalimab, a best-in-class anti-FcRn antibody (recently passing Phase III trials in MG and Phase II/III trials in HDFN). Worked with a CRO to obtain a structure of M281 Fab bound to human FcRn, and used this to explain how it is uniquely suited to blocking IgG binding. Actively use molecular modeling with Schrodinger’s BioLuminate for protein and antibody engineering, humanization, and affinity maturation. Created a humanized antibody with 5-fold better binding than the rodent Ab, and affinity matured a VHH to increase affinity from 2 nM to 200 pM.
Kemp Proteins
View- Website:
- kempproteins.com
- Employees:
- 31
-
Director Of Molecular Biology In Cambridge, MaKemp ProteinsCambridge, Ma, Us
-
Principal Scientist, Head Of Expressions & Htp Protein ProductionTakeda Apr 2021 - Jul 2024Tokyo, JpFormer Head of the Protein Expression Group at Takeda Global Biologics where we express many different antibody and antigen proteins for drug discovery every week. Worked closely with the Biologics Engineering Dept. that needed to screen thousands of antibodies a week. I came up with a unique HTP cloning and expression process that is so efficient that minipreps give perfect DNA sequence data without picking colonies. Our HTPP Team refined this to achieve synthesis, cloning, and expression of plates of proteins in 2.5 weeks. Helped to create a python script to codon optimize input sequences that achieved >95% successful expression. Expression levels of VHH-Fc proteins average >400 µg/ml, and IgG >250 µg/ml. We reformat humanized B-cell Ab, yeast display Ab, and llama VHH hits in a 2.5 week (10 BD) process and can make >2,000 unique, sequence-verified clones per week. We also screen bispecifics and T-cell engagers. This HTP process is greatly enabled by our ability to make these clones without having to pick colonies and to produce the target protein that passes iMS analysis. -
Principal ScientistMomenta Pharmaceuticals Jan 2020 - Mar 2021Cambridge, Massachusetts, UsIn less than 3 months, my team of four plus one co-op expressed and purified >30 antibody candidates at >100 mg scale for animal model screening, engineering several framework modifications along the way, and ultimately discovered the Development Candidate for M281, a best in class anti-FcRn antibody just completing Clinical Phase 2 and 3 trials in Myasthenia Gravis, Rheumatoid Arthritis, Sjorgren’s Syndrome, and HDFN (a first-of-its-kind clinical trial in pregnant women, https://www.nejm.org/doi/10.1056/NEJMoa2314466). Designed the sequence for M281 (Nipocalimab) outside of the VH and VL regions of the aGly IgG1 antibody. Using a CRO, determined the structure of the Fab for Nipocalimab bound to its target, human FcRn, and used this structure to explain why the antibody is best in class. Was co-project Leader of an antibody discovery effort to find antibodies that block collagen binding to integrin a11b1. Discovered three divers antibodies and used Schrödinger to humanize a rodent antibody that increased binding to the antigen 5-fold. -
Senior ScientistMomenta Pharmaceuticals Apr 2006 - Jan 2020Cambridge, Massachusetts, UsLeader of a team to develop Molecular Biology requirements within Research. We cloned and expressed enzymes, receptors and antibodies in HEK and CHO cells. We made highly productive stable cell pools to produce enzymes and clonal cell lines of expressed receptors needed for cell-based assays. We cloned, expressed, and purified novel antibodies as hybridomas and from phage display libraries. I also used Schrödinger Bioluminate to humanize and affinity mature them for use as biotherapeutics. To make in vitro production of hypersialylated-IVIg, M254 (https://www.researchgate.net/publication/337251182), economically viable, >95% pure B4GalT1 and ST6Gal1 enzymes were required at <$10/mg and very low endotoxin levels. This was accomplished by creating HEK293 clonal cell lines that secreted B4GalT1 or ST6Gal1 at > 350 mg/liter. Neither CHO nor E. coli would work for overexpression of either enzyme. Our enzymes had specs that met or exceeded that from Roche Applied Sciences with 10-fold higher expression levels, and the B4GalT enzyme activity was shown to be stable at 37˚C for >10 days. Helped to discover breakthrough in vitro process to increase a2-6 bi-sialylation of Fc-glycans from 60% to >90%.
-
ScientistPfizer Jan 2001 - Jan 2006New York, New York, UsMolecular Biology, cloning, expression, and purification of proteins for crystallography and HTS. Project leader for an antiviral drug discovery project. Led Molecular Biology effort on many projects for Ophthalmology, Cancer and Antiviral projects that were generally focused on Structure-Based Drug Design. Cloned, expressed and purified the many versions of rhinovirus 3C protease for our SBDD driven drug discovery project that led to two compounds going into the clinic, AG7088 and AG7404. Also worked on the research team for Axitinib (AG-13736, Inlyta, Pfizer), a highlypotent and selective VEGFR inhibitor recently approved for the treatment of kidney cancer. -
ScientistWarner Lambert Jan 1998 - Jan 2001UsPfizer took over Warner-Lambert so see above. -
ScientistAgouron Pharmaceutical Inc Apr 1993 - Jan 2001Warner-Lambert purchased Agouron, so see above. -
Senior ScientistAmbion May 1992 - Nov 1993UsIn charge of cloning and expression of enzymes such as RNase I from E. coli and SP6 RNA polymerase. Created and supported several molecular Biology kits including RNAse Protection and RNA transcription.
Jim Meador Skills
Jim Meador Education Details
-
Tulane UniversityChemistry
Frequently Asked Questions about Jim Meador
What company does Jim Meador work for?
Jim Meador works for Kemp Proteins
What is Jim Meador's role at the current company?
Jim Meador's current role is Director of Molecular Biology in Cambridge, MA.
What is Jim Meador's email address?
Jim Meador's email address is jm****@****rma.com
What is Jim Meador's direct phone number?
Jim Meador's direct phone number is +161739*****
What schools did Jim Meador attend?
Jim Meador attended Tulane University.
What skills is Jim Meador known for?
Jim Meador has skills like Protein Expression, Drug Discovery, High Throughput Screening, Molecular Biology, Cell, Antibodies, Biotechnology, Protein Purification, Purification, Protein Engineering, Bioinformatics, Glycobiology.
Who are Jim Meador's colleagues?
Jim Meador's colleagues are Daniel Dibari, Andrew Lyons, Casey Hott Mitchell, Ashley Henson, Christopher Kemp, Sandra Ortega, April Birch Salamon, Pmp.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial